ResearchPUBMEDApr 3
Researchers tested whether artificial intelligence chatbots like ChatGPT could diagnose rare genetic diseases by comparing them to a traditional diagnostic tool called Exomiser. They tested seven different AI models on over 5,000 real patient cases. The study found that even the best AI chatbots were not as accurate as the existing diagnostic tool at identifying the correct disease.
WHY IT MATTERSIf you're waiting for a diagnosis for a rare genetic disease, this research shows that AI chatbots alone shouldn't replace traditional diagnostic tools—your doctor should continue using proven methods alongside any new technology.
Clinical trialCLINICALTRIALSMar 26
Researchers across 7 European countries are working together to develop better ways to diagnose two rare kidney diseases: atypical hemolytic-uremic syndrome (aHUS) and C3 glomerulonephritis (C3G). This study is enrolling 180 people, including patients with these conditions and healthy volunteers, to test new diagnostic tools that could help doctors identify these diseases more quickly and accurately.
WHY IT MATTERSThis trial is developing improved diagnostic tests for aHUS and C3G, which could help patients get diagnosed faster and start treatment sooner—critical since these complement-mediated kidney diseases can cause permanent kidney damage if left untreated.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new genetic tool called RNA-Seq to help diagnose rare diseases in children and adults whose current genetic tests came back negative. This tool looks at how genes are turned on and off in cells, which can reveal problems that standard DNA testing misses. The study will first test the tool in healthy people and those with known genetic conditions, then use it to try to diagnose patients with undiagnosed rare diseases.
WHY IT MATTERSIf you have a child or family member with symptoms of a rare kidney or genetic disease but genetic testing hasn't found answers, this trial could offer a new diagnostic pathway that standard tests have missed.